NEW YORK (GenomeWeb) – Opko Health is hoping for a positive coverage decision from Medicare contractor Novitas as it continues to commercialize its 4Kscore test for prostate cancer.

The company noted during its Q4 2016 earnings call this month that it had expected Novitas to review the test during its February review cycle for draft local coverage determinations, but that the contractor had not yet announced LCDs for the 4Kscore or any other diagnostics in that cycle.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.